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| INTRODUC TI ON
Irritable bowel syndrome (IBS) is one of the most frequently diagnosed disorders in gastroenterology, which can be defined by the Rome IV criteria system. [1] [2] [3] It is characterized by abdominal pain related to defecation, and associated with a change in stool frequency or consistency (diarrhea, constipation, or a combination of these), without any organic disease or pathological abnormality of the gut-wall. 4 Four subtypes of IBS can be separated: diarrheal
(IBS-D), constipation (IBS-C), mixed or alternating (IBS-M/A) and un-
classified (IBS-U) form. 5, 6 IBS can lead to significant quality of life impairment, decreased work productivity and an increase of health care and social costs. [7] [8] [9] [10] The prevalence of IBS is high in Western countries, affecting 10%-20% of the adult population. [11] [12] [13] Its pathogenesis remains unknown, but numerous factors may contribute to its development. 3, [14] [15] [16] Treatment is often multimodal, comprising of non-pharmacological and pharmacological methods. A novel effective treatment option is a low-FODMAP diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols), which suggests that certain food types, containing disaccharides like lactose, can trigger symptoms of patients with IBS. [17] [18] [19] Lactose intolerance (LI) is a condition characterized by clinical symptoms after ingestion of lactose-containing products, caused by lactose maldigestion (LM). 20 The most common cause of LM is primary (adult-type) hypolactasia. 3 LI affects 25% of the Caucasian population. Males and females are equally affected. 21, 22 Because of lactase deficiency, lactose can reach the large intestine where it is fermented by colonic bacteria. Short-chain fatty acids, gases (H 2 , CO 2 and CH 4 ) and other products will be produced by the fermentation which can cause luminal distension and lead to different gastrointestinal symptoms. The most common complaints are abdominal pain and discomfort, bloating, flatulence, and diarrhea, similarly as in IBS. 20, [23] [24] [25] Due to the potential pathogenetic factors of IBS (altered gastrointestinal motility, changes of gut microbiome, visceral hypersensitivity, anxiety, etc), food intolerances, such as LI, are more frequent in this disease, however, the prevalence of LM does not differ compared with the healthy population. More IBS patients have symptoms at lower lactose doses and their symptoms are more severe. Moreover, many IBS patients think that their abdominal symptoms are related to lactose intake, even though no objective tests of LM were carried out. [26] [27] [28] [29] [30] The available diagnostic methods for diagnosing LM or LI are based on several approaches, including lactose breath test (LBT), lactose tolerance test (LTT), genetic test and assessment of lactase activity in jejunal biopsy specimens. 3 The restriction of lactose intake or the replacement of the lactase enzyme can alleviate these symptoms. 3, 21 There are numerous clinical trials investigating the connection between IBS, LM, and LI, but to our best knowledge no meta-analyses have been performed up to this day.
Given the uncertain connection between IBS and lactose consumption-related disorders, we performed a systematic literature search and meta-analysis in this important topic with the aim to assess the prevalence of LM, objective and subjective LI in IBS patients compared to healthy controls (HC).
| MATERIAL S AND ME THODS
Our work was planned and conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) 2009 Statement (Table S1 ).
| Searching strategy
Our systematic literature search was based on the PICO format:
Participants: subjects who underwent any form of LM or LI assess- 
Key Points
• The connection between IBS and lactose intolerance is not clearly described yet, therefore we performed meta-analysis to explore this association.
• We proved that lactose intolerance is more common in IBS, however, the frequency of lactose maldigestion is almost the same compared to healthy people.
• This suggests that IBS is a possible contributing factor in lactose intolerance among lactose maldigesters.
Outcomes: prevalence of LM, subjective/objective LI. It was conducted by two independent reviewers (JC and PV) to find all relevant articles on the prevalence of LM, subjective and objective LI in IBS compared to HCs, up to 24 April 2018 (first search: 20 June 2017). The search covered three major databases (PubMed, Embase, and the Cochrane Library) with the terms "('irritable bowel syndrome' OR 'IBS') AND ('lactose intolerance' OR 'lactose maldigestion' OR 'lactose malabsorption')." The reference lists of the relevant articles were hand searched and all appropriate records identified were included in the screening process. After this search process, language (only English) and species (only humans) filters were used.
Duplicates were removed with EndNote X4 and manually, and then title and abstract screening was performed by the two reviewers to identify potentially eligible articles. Disagreements were resolved by consensus.
| Eligibility criteria
In our meta-analysis, we included all studies investigating the connection between IBS, lactose consumption-related symptoms, and maldigestion in comparison with HC group. Retrospective studies were also included. 
| Quality assessment of the individual studies
The quality and the biases of the included studies were analyzed with the Newcastle-Ottawa Scale (NOS) for case-control studies. 31 Two authors (IMC, PV) independently assessed the risk of bias in each paper included in the statistical analysis. Disagreements were resolved by consensus. If the discussion did not result in consensus, a third author was consulted (PH). The NOS for case-control studies contains eight items covering three main domains (selection, comparability and exposure). A study can be awarded a maximum of one star for each numbered item; on the contrary, a maximum of two stars can be given for comparability. Each item was rated as "high risk" (zero stars), "low risk" (one star) or "unclear risk" (zero stars)
corresponding to the definitions.
| Data extraction
At the end of the screening process, relevant data were independently extracted from studies by two independent reviewers (JC and PV). These included: prevalence of LM and LI (subjective or objective) as the outcome parameters, first author, year of publication and country of origin, study design, basic characteristics of the study population (age, percentage of females and IBS subtypes, size of the study groups), diagnostic criteria for IBS, diagnostic methods, thresholds and lactose dose used to diagnose maldigestion. Data for the risk of bias (NOS) assessment were collected as well. Extracted data were validated by five co-authors (ZsSz; DP; MB; ÁV; JT).
| Outcome measure
The prevalence of LM, subjective and objective LI were the main outcome parameters in our analysis. LM can be diagnosed through different ways, 21 the non-invasive and inexpensive LBT and LTT being the most common methods. The sensitivity and specificity of these tests depends on the lactose dose, but they are relatively high (78% and 93%). 
| Statistical analysis
Pooled odds ratios (OR) were calculated with 95% confidence intervals (CI). Random effects and fixed model were applied at all of analyses with DerSimonian-Laird 33 estimation. Statistical heterogeneity was analyzed using the I 2 and the chi-square test to gain probability-values; P < 0.1 was defined to indicate significant heterogeneity. 34 Subgroups of test type (LBT, LTT, lactase activity, and genetic test) and lactose dosages (10-18 g, 20-25 g, and 40-50 g) were created in the analysis on the outcomes. Statistical analyses were performed using the Comprehensive Meta-Analysis Software (CMA, Biostat, NJ, USA). Forest plots were used to present the results of the meta-analyses. To check for publication bias, the visual inspection of funnel plots and Eggers' tests were performed.
| RE SULTS

| Search results
Using the terms mentioned above, we found 647 articles in the three databases for evaluation, 213 in PubMed, 413 in Embase and 21 in Cochrane Library. We also examined 14 further articles from the reference lists of relevant articles, so 661 articles were found in total. After using the language (only English) and species ( At the time of the literature search, we found no eligible paper that used the most recent diagnostic criteria (Rome IV) for IBS. The basic characteristics of the articles and the raw data are summarized in Tables 1 and S2 . The proportion of each IBS subtype and the used lactose doses, diagnostic methods for LM and thresholds in the studies included in the meta-analysis are detailed in Table 2 .
A quality assessment (NOS) of the articles is summarized in Tables   3 and S3 .
| Lactose maldigestion and IBS
In 13 of the 14 articles, LM was objectively tested with LBT, LTT or genetic testing. There were not enough controlled studies with lactase activity measurement to carry out a correct statistical analysis. In one of the included case-control studies, only subjective LI was assessed. There was no significant heterogeneity within the subgroups.
| Lactose intolerance
Only four case-control studies published data about self-reported (subjective) LI. 26, 37, 41, 42 Our results ( Figure 5 ) showed that subjective LI was more common in IBS compared to HCs, patients reported more often that their abdominal symptoms can be related to lactose-containing products (OR = 3.499; 95% CI: 1.622-7.551; P = 0.001). The examined population was significantly heterogeneous (I 2 = 86.774%; P = 0.000).
There were three articles available reporting on objective LI ( Figure 6 ). 26, 27, 46 Significantly more maldigester IBS patients reported abdominal symptoms during or shortly after the diagnostic test compared to controls (OR = 2.521; 95% CI: 1.280-4.965; P = 0.008), but our result is limited by the heterogeneity of the analyzed population (I 2 = 74.866%; P = 0.003).
TA B L E 3
The quality and risk of bias assessment of the included studies according to Newcastle-Ottawa Scale for case-control studies The NOS consists of eight numbered items, divided into three main sections (selection, comparability, and exposure). Each numbered item can be rewarded with maximum one star; comparability can be awarded with two stars. The studies with maximum of nine stars representing the highest-quality trials with the lowest risk of bias. The detailed analysis of each study is represented in Table S3 . NOS, Newcastle-Ottawa Scale.
F I G U R E 2
The difference of LM between IBS and HCs, based on the ingested lactose dose (10-18 g, 20-25 g, 40-50 g). There was no significant difference either overall, or in the subgroups. HC, healthy controls; IBS, irritable bowel syndrome; LM, lactose maldigestion
The difference of LM between IBS and HCs, based on the lactose dose and diagnostic method. LM was significantly more frequent in IBS only at the LBT with the highest lactose dose (40-50 g). HC, healthy controls; IBS, irritable bowel syndrome; LBT, lactose breath test; LM, lactose maldigestion
The difference of subjective (self-reported) LI between IBS and HCs. Subjective LI was significantly (P = 0.001) more frequent in IBS compared to the control group. HC, healthy controls; IBS, irritable bowel syndrome; LI, lactose intolerance
The difference of LM between IBS and HCs, based on the diagnostic method (LBT, LTT, genetic test). There was no significant difference either overall, or in the subgroups. HC, healthy controls; IBS, irritable bowel syndrome; LBT, lactose breath test; LM, lactose maldigestion; LTT, lactose tolerance test
| D ISCUSS I ON
A growing number of studies have shown that intolerance to lactosecontaining products and other food types is more frequent among patients with IBS than among healthy subjects, but to our best knowledge, no meta-analysis investigated the association between these two conditions so far. Only two recent reviews by Borghini and Bayless et al. 3, 47 discuss the correlation between IBS and LI.
We carried out a systematic literature search and quantitative data (meta-) analysis on the topic. A pooled analysis of 14 case-control trials confirmed a significantly higher prevalence of subjective and objective LI, whereas nearly the same prevalence of LM in IBS patients compared to healthy participants. The underlying mechanism remains unknown, but common etiological factors like psychological (eg anxiety) and gastrointestinal dysfunctions (eg visceral hypersensitivity and altered gut transit) might play a role. [28] [29] [30] The visceral hypersensitivity can also be in connection with altered gut microbiome.
Gut microbiota of IBS patients is generally reduced and has lower diversity, compared to healthy controls. 48 It has been shown that potentially pathogenic bacteria (eg Clostridium spp, Ruminococcus spp, Streptococcus spp, Enterobacteriaceae members) are more concentrated in IBS patients than in controls. [49] [50] [51] [52] A recent MRI (magnetic resonance imaging) study concluded that visceral hypersensitivity, rather than excessive gas production is responsible for carbohydrate associated symptoms in patients with IBS. 53 The hypersensitivity to colonic distension can be transferred to mice by fecal transplantation which highlights the role of microbiome. 54 Moreover, gut microbiota produces many neuroactive or neuromodulatory metabolites (histamine, serotonine, gamma-aminobutyric acid, brain derived neurotrophic factor, etc), which can potentially lead to peripheral or central neural sensitization. 55, 56 Most studies have shown a beneficial effect of lactose-free or restricted diet in IBS. 25, 57, 58 One reason might be that lactose belongs to FODMAPs, which are poorly absorbed carbohydrates leading to increased water content in the bowel based on the compounds' osmotic effect and increased gas production by colonic bacterial flora, inducing symptoms in patients with IBS and numerous patients with functional gastrointestinal disorders. Based on these findings, a low-FODMAP diet could be beneficial in these patients. [17] [18] [19] In the present study, the pooled sample size was large concerning the key question and the random effects and fixed model were used with the DerSimonian and Laird method 33 for analysis. Study data reflected no publication bias according to the analyses of LM status (Figures S1, S2 and S3), but showed significant bias (small study effect) based on heterogeneity in forest plots of subjective and objective LI ( Figures S4 and S5 ).
We evaluated the quality of the studies included in the metaanalysis with the NOS for case-control studies, which showed satisfactory scores of the trials with low or medium risk of bias (Tables 3 and S3 ).
The strength of our study is that standardized, well-defined, rigorous outcome measures were used to assess the role of lactose consumption-related disorders in IBS patients, and a sufficient number of articles were found to carry out a detailed statistical analysis. Only full-text papers were enrolled, where IBS patients with appropriate control groups were present. According to our results, more IBS patients reported themselves lactose intolerant before any objective tests compared to HCs, which can be highlighted with objective measures: significantly more maldigester IBS patients reported abdominal symptoms during or shortly after the diagnostic test (objective LI). However, except for the LBT with the highest lactose doses (40-50 g ), the prevalence of LM was similar in the study groups. Our meta-analysis is the first to provide evidence for the connection between IBS and LI and our former 18 data suggest that a lactose-free or lactose-restricted diet (low-FODMAP) in the treatment of IBS could improve the therapeutic effect on IBS symptoms and might decrease health care-related and societal costs.
There are some limitations of our study. Firstly, we focused on the prevalence of LM and subjective/objective LI, and due to the lack of detailed, uniform, controlled, published data, we could not 21 Another difficulty is that it is hard to identify the food, responsible for the symptoms. The correlation between self-reported and objective LI increases with the ingested lactose dose. 26 Finally, we found significant heterogeneity in the analysis of the subjective and objective LI. We could not perform subgroup analysis with different amount of lactose in LI, however, it can influence the frequency and severity of the abdominal symptoms and therefore the prevalence of objective LI, as presented by Yang et al. 
| CON CLUS ION
This meta-analysis is the first to confirm that subjective and objective LI are more common in IBS patients compared to the healthy population, but LM has the same prevalence. Based on these findings and literature data, IBS can be a contributing factor of LI among people with LM. Further studies are needed to determine whether a confirmed diagnosis of IBS is an etiological factor in determining
whether LM patients present with LI.
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